In a filing with the US Securities and Exchange Commission (SEC), Canadian biotech Zymeworks has revealed the sudden replacement of its chief financial officer. 4 April 2024
A new chief medical officer will take the reins at Shanghai-based biotech Everest Medicines, as the drug and vaccine firm undertakes a minor reshuffle at the to 18 March 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.